There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Sarepta Therapeutics (SRPT – Research Report), ...

Sarepta Therapeutics (NASDAQ:SRPT – Free Report) had its price target reduced by Royal Bank of Canada from $165.00 to $161.00 ...

Sarepta Therapeutics (NASDAQ:SRPT – Get Free Report)‘s stock had its “sell” rating reiterated by stock analysts at HC ...

In a report released today, Andreas Argyrides from Oppenheimer reiterated a Buy rating on Sarepta Therapeutics (SRPT – Research Report), with a ...

Q4 2024 Earnings Call Transcript February 26, 2025 Sarepta Therapeutics, Inc. beats earnings expectations. Reported EPS is $1 ...

Sarepta Therapeutics Inc (SRPT) reports a 75% increase in quarterly revenues and outlines ambitious growth plans for 2025.

Good afternoon, and welcome to the Sarepta Therapeutics fourth quarter and full year 2024 financial results conference call.

CAMBRIDGE, Mass. - Sarepta Therapeutics (NASDAQ: SRPT) reported fourth quarter earnings that beat analyst expectations, but the stock fell 4.6% as investors focused on rising expenses.

Biotech company Sarepta Therapeutics (NASDAQ:SRPT) announced better-than-expected revenue in Q4 CY2024, with sales up 65.9% ...

The price trend for Sarepta Therapeutics (SRPT) has been bearish lately and the stock has lost 9% over the past four weeks.

We recently compiled a list of the 15 Stocks That Will Go to The Moon According to Analysts. In this article, we are going to ...